BioXcel Therapeutics, Inc. (BTAI): Price and Financial Metrics
GET POWR RATINGS... FREE!
BTAI Stock Price Chart Interactive Chart >
BTAI Price/Volume Stats
| Current price | $30.70 | 52-week high | $67.74 |
| Prev. close | $30.61 | 52-week low | $23.07 |
| Day low | $30.41 | Volume | 777,600 |
| Day high | $32.00 | Avg. volume | 437,802 |
| 50-day MA | $26.97 | Dividend yield | N/A |
| 200-day MA | $38.53 | Market Cap | 858.65M |
BioXcel Therapeutics, Inc. (BTAI) Company Bio
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. The company was founded in 2017 and is based in Branford, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Latest BTAI News From Around the Web
Below are the latest news stories about BioXcel Therapeutics Inc that investors may wish to consider to help them evaluate BTAI as an investment opportunity.
BTAI: Encouraging Data for BXCL701 in Heavily Pretreated mCRPC Patients…By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update Encouraging Data for BXCL701 in Heavily Pretreated mCRPC Population On September 15, 2021, BioXcel Therapeutics, Inc. (BTAI) announced that data from the ongoing Phase 1b/2 clinical trial of BXCL701 in patients with metastatic castration-resistant prostate cancer (mCRPC) was presented at the 2021 European Society |
BioXcel Therapeutics Presents Results from Ongoing Phase 2 Trial of BXCL701 in Combination with KEYTRUDA® in Aggressive Forms of Prostate Cancer at ESMOBXCL701 plus KEYTRUDA® (pembrolizumab) demonstrates encouraging anti-tumor activity in heavily pre-treated mCRPC patients with adenocarcinoma BXCL701 combination continues to exhibit favorable safety profile; patient enrollment continues as per protocol NEW HAVEN, Conn., Sept. 15, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno |
BioXcel Therapeutics to Present Updates from Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2021 ESMO CongressNEW HAVEN, Conn., Sept. 12, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that updates from its ongoing Phase 1b/2 trial of BXCL701, the Company''s investigational, oral innate immunity activator, in aggressive forms of prostate cancer will be presented in a poster session at the 2021 European Society for Medical Oncology (ESMO) Congress, which will take place virtually from September 16-21, 2021. |
BioXcel Therapeutics to Host Virtual R&D Day on September 23, 2021Live webcast, Revolutionizing Drug Discovery and Development Through AI , to be held from 12:00 PM ET 2:00 PM ET |
BTAI: PDUFA Date of Jan. 5, 2022 for BXCL501By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update PDUFA Date for BXCL501 of January 5, 2022; MAA Submission Expected 2H21 In May 2021, BioXcel Therapeutics, Inc. (NASDAQ: |
BTAI Price Returns
| 1-mo | 26.49% |
| 3-mo | -16.69% |
| 6-mo | -23.97% |
| 1-year | -36.57% |
| 3-year | 307.16% |
| 5-year | N/A |
| YTD | -33.55% |
| 2020 | 216.22% |
| 2019 | 278.50% |
| 2018 | N/A |
| 2017 | N/A |
| 2016 | N/A |
Loading social stream, please wait...